With reference to letter dated January 8, 2020 intimating the Company has redeemed the outstanding Non-Convertible Debentures along with accrued interest thereon on January 7, 2020 and pursuant to the provisions of Regulation 57(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Jubilant LifeScience has informed that the Company has provided all the documents and intimations required to be submitted to the Debenture Trustee, Vistra ITCL (India) during the Financial Year 2019-20 in terms of the Debenture Trust Deeds and the SEBI (Issue and Listing of Debt Securities) Regulations, 2008.
The above information is a part of company’s filings submitted to BSE.
